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The 𝛽2-adrenergic receptor (𝛽2AR) is a seven-transmembrane (7TM) G-protein coupled receptor that is expressed on cells of the
pulmonary, cardiac, skeletal muscle, and immune systems. Previous work has shown that stimulation of this receptor on immune
cells has profound effects on the regulatory activity of both adaptive and innate immune cells. This review examines the functional
dichotomy associated with stimulation of 𝛽2AR and microglial cells. As well, recent studies targeting these receptors with long-
acting agonists are considered with respect to their therapeutic potential in management of Parkinson𝜇s disease.
1. Introduction
Neurodegenerative disorders, such as Alzheimer’s, Hunting-
ton’s, and Parkinson’s disease, are characterized by the pro-
gressive loss of the structure and function of neurons. Specif-
ically, Parkinson’s disease is characterized by the death of
dopaminergic (DA) neurons (cell groups A8 and A9) in the
midbrain, substantia nigra (SN), and striatum.Over time, this
leads to impaired motor skills, shaking, slowness of move-
ment, and postural instability, well known symptoms of PD.
In addition, many patients experience dementia and execu-
tive dysfunction. A recent study of an unselected population-
representative cohort (𝑛 = 142) highlights the poor prognosis
of PD patients as evidenced by a 55%mortality rate within 10
years of diagnosis [1]. Of the survivors, 68% and 46%had pos-
tural instability and dementia, respectively; 23% had not yet
progressed to either of these irreversible disease milestones.
Since the late 1960s, levodopa has been a key treatment
and is the gold standard nearly 50 years later [2]. Converted
to dopamine within the brain, it is used to control the motor
symptoms of the disease but is ineffective with respect to
dementia, freezing, or autonomic functions. A host of other
treatments have been developed centered primarily around
maintaining or increasing dopamine concentrations within
the brain, such as dopamine agonists, MAO B inhibitors, cat-
echol o-methyltransferase (COMT) inhibitors, anticholiner-
gics, and amantadine. Stem cell transplant therapy and deep
brain stimulation have also been explored with varying
results.
What is known about neurodegenerative disorders in
general and in Parkinson’s disease in particular is that the
progressive nature is in part associated with chronic inflam-
mation and microglial activation [3]. Although a variety of
triggers, including inherited genetic mutations and environ-
mental toxins, can initiate the advent of neurodegeneration,
inflammation is now recognized as an underlyingmechanism
that drives the progressive nature of Parkinson’s disease [4–8].
As such, this review will examine the research exploring
potential therapeutic targets aimed at abrogating the inflam-
matory dysfunction.
2. The Dysfunctional Immune System in
Parkinson’s Disease
Well over two decades ago, it was first recognized that acti-
vatedmicroglia and neuroinflammation were associated with
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Figure 1: Model of neurodegeneration attributed to reactive microgliosis in Parkinson’s disease.
the SN lesions of PD patients when observed postmortem
[8, 9]. Additionally, an accidental human neurotoxin model
of Parkinson’s disease also implicated activated microglia
and chronic neuroinflammation in progressive loss of SN
neurons [10, 11]. In this report, a group of drug users were
exposed at relatively young ages to 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) as a contaminant in street-drugs.
Each developed progressive Parkinsonian symptoms years
after exposure. Postmortem analyses indicated the presence
of neuroinflammation, activated microglia, and active neu-
rodegeneration in the SN up to 15 years after systemic expo-
sure to the MPTP contaminant [11]. Similar findings resulted
from experiments with a long-term primate model of MPTP-
induced SNdegeneration [12].These studies demonstrate that
once a trigger initiates neuroinflammation in the SN, the
condition can persist for long periods causing progressive loss
of DA neurons.
Microglia are the innate immunity cells resident in the
brain and are amajor source of proinflammatory factors, such
as tumor necrosis factor 𝛼 (TNF𝛼), interleukin-1 𝛽 (IL-1𝛽),
interleukin-6 (IL-6), reactive oxygen species (ROS), and
nitric oxide as well as many others [3]. Microglia can also
play beneficial roles in maintaining brain homeostasis and
produce factors involved in neural cell survival, proliferation,
growth, and motility. Microglia also secrete anti-inflamma-
tory factors, including transforming growth factor 𝛽 (TGF-
𝛽). As active immune sentinels,microglia have been observed
in vivo to continuallyextendprocesses toprobe theirmicroen-
vironment even when in the so-called “resting” state [13].
However, after insult, microglia are rapidly activated, migrate
to the site of injury, and phagocytose injured and dying cells
[13].
In Parkinson’s disease, it is these activated microglia that
become self-propellingmediators of neuronal cell death lead-
ing to chronic inflammation. Once a trigger induces initial
injury or death ofDAneurons, activatedmicroglia perpetuate
the death of more neurons through the cyclic processes of
pro-inflammatory reactive microgliosis [3, 14, 15]. In this
manner, microglia mediate the progressive loss of DA neu-
rons giving rise to characteristic postmortem PD reports of
activated microglia, chronic inflammation, and loss of DA
neurons within the SN. We have developed a model for the
etiology of progressive Parkinson’s disease (Figure 1). In this
model, we believe that a direct neurotoxin, such as MPTP, or
an inflammatory trigger, such as LPS, can lead to the direct
or indirect activation of microglia. Animal models of neu-
rodegeneration triggered by toxin exhibit similar progressive
destruction of the SN.
3. 𝛽2-Adrenergic Receptors
Microglia express high levels of 𝛽2AR at the cell surface
[16]. Interestingly, several studies found that depletion of the
endogenous 𝛽2AR agonist, norepinephrine (NE), caused
increased microglial-induced neuroinflammation and that
administration ofNEprotects cortical neurons frommicrogl-
ial-induced cell death [17, 18]. Furthermore, NE adminis-
tration dose-dependently blocked microglial expression of
the inflammatory mediators NOS2 and IL-1𝛽, and these anti-
inflammatory effects could be completely reversed by coap-
plication of the 𝛽2AR-specific antagonist, ICI-118,551 [18].
Together, these findings implicate 𝛽2AR as playing a key reg-
ulatory role in microglia activation.
Specifically, in humans the 𝛽2-adrenergic receptor
(𝛽2AR) is a 413 amino acid long glycoprotein that is a mem-
ber of the seven-transmembrane (7TM) family of G-pro-
tein coupled receptors [19, 20]. Adrenergic receptors are
subdivided into three groups (𝛽1, 𝛽2, and 𝛽3) which are
expressed in a variety of cell and tissue types, with the 𝛽2AR
subtype classically occurring in the various cells of the
pulmonary, cardiac, skeletal muscle, and immune systems
[19]. Therapies that modulate 𝛽2AR responses are well docu-
mented for uses in treating asthma and other respiratory
diseases, as well as hypertension and angina.
4. 𝛽2AR Agonists
Beta-adrenergic receptor agonists are a group of drugs that
are mimetics of endogenously occurring catecholamines,
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including epinephrine, norepinephrine, and dopamine. Ago-
nists can be either direct interacting with the receptors or
indirect in that they do not stimulate receptor activation but
induce the release of endogenous catecholamines. There are
multiple synthetic 𝛽2AR agonists which act mainly in the
smooth muscle and endothelial cells of the pulmonary sys-
tem, vasculature, bronchial tree, colon, and uterus. 𝛽2AR
agonists have two functional forms: short-acting agonists
used predominantly as fast-acting bronchodilators in treating
asthma and other acute bronchial disorders, and long-acting
agonists that are used to manage and control chronic, long-
term bronchial diseases, such as chronic obstructive pul-
monary disease (COPD). 𝛽2AR agonists have also been used
to prevent premature labor by administration systemically to
act upon the smooth muscle of the uterus.
4.1. Short-Acting versus Long-Acting 𝛽2AR Agonists. The
molecular characteristics of the particular agonist determine
the mode of interactions with 𝛽2AR and ultimately the man-
ner in which downstream effects are generated. Agonists that
have hydrophilic properties are able to access the receptor
directly from the aqueous extracelluar environment. These
agonists thus have relatively rapid effects and are generally
termed “short-acting” due to the rapid onset and short dura-
tion of their stimulatory activity upon the receptor. Long-
acting agonists are generally lipophilic and are taken up into
the cell membrane where they slowly leach-out to access the
𝛽2AR over longer periods of time, thus producing more long
lasting effects [19, 21]. Studies have shown that the 𝛽-ARs are
also stereospecific and that this enantiomeric specificity can
be important for agonist-induced functional responses from
the stimulation of the receptor [22]. Furthermore, stereos-
electivity by the receptor can determine the immunomod-
ulatory effects of 𝛽2AR stimulation, especially with regards
to the response of activated macrophages [19, 22]. However,
studies have also shown in a model of cerebroischemic stroke
that while two enantiomers of a lipophilic 𝛽2AR-agonist pro-
vide neuroprotection by activating astrocytes and inducing
production of neurotropic factors, one racemate might also
induce more adverse side-effects [23, 24].
5. 𝛽2AR Agonists in Neuroprotection
Long-acting 𝛽2AR agonists that are typically used as bron-
chodilators in the treatment of asthma have also shown to
have trophic effects in tissue culture models of CNS injury
[25, 26]. Up-regulation of 𝛽2ARs after brain damage in vivo is
associated with astrocyte activation and neuroprotection [27,
28]. Induction of neurotrophic growth factors and astrocyte
activation by long-acting 𝛽2AR-agonists has been found
to mediate neuroprotection in several in vivo models of
neuronal damage [23, 29, 30]. 𝛽2ARs are also expressed in
microglial cells and have been shown to mediate the inhibi-
tion of microglia activation [31]. However, 𝛽2AR antagonists
are reported in another study to block IL-6 production and
acute inflammatory response, as well as to provide neuro-
protection in a model of hemorrhagic stroke [32]. In con-
trast, the same antagonist (butoxamine) did not have any
neuroprotective effect in a model of focal cerebral ischemia
[30]. In fact, in this model butoxamine actually abrogated the
neuroprotection provided by treatment with 𝛽2AR agonists
[30]. It is suggested that the different results for neuropro-
tection have more to do with the two different models of
stroke brain-damage and the mechanisms responsible for the
damage [33]. Additionally, in a rat model of traumatic brain
injury (TBI), stimulation of 𝛽2AR with agonist decreased
brain function impairment and improved recovery after
injury [34].This latter study found that the agonist stimulated
neuroprotection after TBI correlated with decreased levels
of blood glutamate levels which are typically elevated in
response to injury and are generally neurotoxic [34]. How-
ever, a major caveat in interpreting all of these studies is that
the models required pretreatment with the 𝛽2ARs agonists
(or antagonist) in order for neuroprotection. In contrast,
in an LPS-stimulated chronic model of Parkinson’s disease,
treatment with the long-acting agonist salmeterol after initi-
ation of the disease prevented neurotoxicity via inhibition of
reactive microglia [35].
6. 𝛽2AR Agonists in the Treatment of
Parkinson’s Disease
In 2011, we looked at the effects of both the short-acting
𝛽2AR agonist, salbutamol, and a variety of long-acting 𝛽2AR
agonists, including salmeterol, on the survival of DA neurons
after induction of inflammation in different disease models
of Parkinson’s disease [35]. In mixed cell-cultures composed
of primary mesencephalic neurons and glial cells that were
treated with LPS, the long-acting agonists protected DA neu-
rons from inflammation-induced cytotoxicity as did salbu-
tamol. However, a short-acting agonist was able to confer
neuro-cell protection only at much higher concentrations. In
contrast to these beneficial effects in an inflammation-based
model of neurotoxicity, we found that salmeterol treatment
had less pronounced protective effects in a similar mixed
cell model which featured induction of DA neuron death by
MPTP. The MPTP metabolite MPP+ mediates direct toxicity
on the neurons themselves and this neuronal death leads to
the induction of reactive microgliosis, whereas LPS-induced
neurotoxicity is mediated by the direct action of LPS on
microglial cells leading to their production of inflammatory
mediators, which leads to neuronal death and the continuing
cycle of reactive microgliosis [3, 36]. However, when tested
in two in vivo models of PD, the LPS-stimulated long-term
mouse model and the acute MPTP model, salmeterol also
exhibited some neuroprotective effects either by pretreatment
(in the LPS-induced model) or by treatment with salmeterol
post MPTP-injections respectively. These results suggested
to us that long-acting 𝛽2AR agonists, such as salmeterol,
might be developed for their anti-inflammatory effects to
attenuate the progressive loss of DA neurons characteristic in
Parkinson’s disease and improve motor activity in patients.
Additional studies using non-MPTP models of PD should
help determine whether use of agonists such as salmeterol
could prove beneficial in the management of Parkinson’s
disease.
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7. 𝛽2AR Agonists and Signaling Pathways
In addition to their role in stimulating G-protein coupled sig-
naling, 𝛽2AR agonists also transduce signals from the recep-
tor through its association with 𝛽-arrestins [37]. In addition
to mediating receptor desensitization through blocking G-
protein coupling with 𝛽2AR [38], 𝛽- arrestin can also link
𝛽2AR to the activation of other signaling pathways, such as
the MAPK signaling cascade and the kinase complex that
regulates activation/inhibition of the transcription factor,
NF-𝜅B [37, 39]. Earlier studies found that the inflammatory
effects of 𝛽2AR agonists at high concentrations were medi-
ated through 𝛽2AR-induced cAMP production [40–42].
However, Qian and colleagues showed that, in primary
murine-microglia cultures, the addition of low concentra-
tions of salmeterol inhibited the LPS-induced production of
inflammatory mediators, such as reactive oxygen species
(ROS), TNF𝛼, and nitric oxide (NO) [35]. This inhibition is
𝛽2AR and 𝛽-arrestin dependent but cAMP independent [35].
Thus, low doses of salmeterolmight inhibit inflammation and
promote neuroprotection by regulating receptor association
with 𝛽-arrestins and 𝛽-arrestins-mediated function in other
signaling pathways such as NF-𝜅B pathway and the MAPK
signaling cascade.
7.1. Anti-Inflammation and NF-𝜅B. It has been shown that
𝛽2AR agonists, at low concentrations, stimulate anti-inflam-
matory effects by negative regulation of the transcription
factor NF-𝜅B [39]. 𝛽-arrestin2 is a binding partner of I𝜅Ba
which is an inhibitor of NF-𝜅B activation [39]. NF-𝜅B is a
ubiquitously expressed transcription factor that regulates
transcription of genes involved in immunity and inflamma-
tion [43]. Five members of the NF-𝜅B/Rel family of proteins,
including p50, p52, p65 (RelA), c-Rel, and RelB, are expressed
in mammalian cells. These NF-𝜅B proteins form various
homo- and hetero-dimers in the cell cytosol where they are
held in the inactive state by association with inhibitory
proteins called I𝜅Bs [44]. A variety of signaling pathways
converge at a kinase complex (NF-𝜅B-inducing kinase/NIK
and I𝜅B kinase/IKK𝛼-IKK𝛽-IKK𝛾) that regulates NF-𝜅B
activation by controlling the association with I𝜅Bs. When
activated, the catalytic subunits of this kinase complex (IKK𝛼
and IKK𝛽) phosphorylate I𝜅B𝛼 and target it for degradation.
Degradation of I𝜅B𝛼 releasesNF-𝜅Bandunmasks the nuclear
signal domain which targets NF-𝜅B translocation to the
nucleus where it binds to the 𝜅B site, and is functionally
active in transcription of inflammatory genes. In this way,
regulation of NF-𝜅B transcription activity depends upon
interaction with I𝜅B, and in turn, proteins such as 𝛽-arrestin
that bind the I𝜅B kinase complex and regulate I𝜅B are critical
for regulating both I𝜅B and NF-𝜅B. Low-dose salmeterol
has been shown to inhibit NF-𝜅B activation suppressing its
translocation to the nucleus [35]. Thus the beneficial effects
of salmeterol might be exerted at least in part through 𝛽-
arrestin-mediated control of NF-𝜅B.
7.2. Anti-Inflammation and MAPK. Activation of 𝛽2AR can
also stimulate the MAPK signaling cascade via a G-pro-
tein-independent but 𝛽-arrestin-dependentmechanism [45].
Previous studies also showed that activation of 𝛽2AR with
high concentrations of salmeterol (10−5M to 10−6M)
induced the MAPK signaling pathway leading to increased
phosphorylation of ERK1/2 and resulting in proinflammatory
effects inmacrophages and primarymicroglia [46]. However,
this proinflammatory effect is mediated through activation
of the cAMP pathway, although it is PKA-independent. Of
key interest is that these same high doses of salmeterol
increased neurotoxicity in mixed cell cultures and that this
was mediated through increased NADPH oxidase activity
through an ERK-dependent pathway [47]. Conversely, low
concentrations of salmeterol greatly reduced the LPS-stim-
ulated phosphorylation/activation of components of the
MAPK, namely, ERK1/2, p38, and JNK [35]. Thus, lower
concentrations of the 𝛽2AR agonist apparently produce anti-
inflammatory effects by inhibiting both MAPK cascade sig-
naling and NF-𝜅B activation. Further supporting evidence is
that low-dose salmeterol inhibits a common upstream effec-
tor for both MAPK and NF-𝜅B; TGF-beta activated kinase 1
(TAK1) has been shown to be a key regulatory component
in various signaling pathways involved in immunity and
inflammation [48]. Both MAPK and NF-𝜅B are downstream
targets of TAK1 which is also the convergent effector for
LPS/TRL- and TNF𝛼-stimulated inflammation. Low doses of
salmeterol (10−9M and 10−10M) can inhibit the activating
phosphorylation of TAK1 in primarymicroglia.This suggests
that the inhibitory effect on MAPK signaling and NF-𝜅B
activation involves inhibition of TAK1. However, the link(s)
between inhibition of TAK1 and the 𝛽-arrestin-dependent
anti-inflammatory effects of low-dose salmeterol has yet to
be determined.
7.3. Anti-Inflammatory Effects of Low-Dose Salmeterol. Pre-
vious results have shown that 𝛽2AR agonists are known to
activate MAPKs via both Gs-dependent and Gs-independent
mechanisms. A Gs-independent increase in phosphorylation
of ERK occurres following high doses of salmeterol treatment
in RAW264 macrophage cells and primary microglia cells
[46], which mediates a proinflammatory and neurotoxic
effect [47]. Conversely, much lower doses of salmeterol
(10−10 −10−11M) have no proinflammatory effects but rather
show dramatic inhibition of MAPK molecules ERK, JNK,
and p38 in LPS-activated primary microglia. Although both
effects appear to work independently of PKA activation, the
proinflammatory effect of high-dose salmeterol is through
the activation of the cAMP/EPACpathway, and the inhibitory
effect of low-dose salmeterol is independent of cAMP induc-
tion as well as PKA and EPAC activity. Rather, it appears
as though the inhibitory activity of salmeterol is due to
the activation of 𝛽-arrestin-2, which functionally inhibits
both NF-𝜅B [39] and MAP-K [49]. In addition, low doses
of salmeterol have a significant inhibitory effect on the
LPS-mediated activation of NF-𝜅B and the production of
inflammatory mediators normally under NF-𝜅B and MAP-
K regulation, such as TNF-𝛼 and NO. However, this anti-
inflammatory action of salmeterol may be selective only
for certain proinflammatory pathways in microglial cells

























Figure 2: Molecular mechanism of the inhibitory function of salmeterol-mediated 𝛽2AR activation.
because low-dose salmeterol is able to inhibit the activation
of superoxide production by LPS but not by PMA (which
functions through the PKC pathway). Therefore, it appears
that low-dose salmeterol can be potently but selectively anti-
inflammatory in microglial cells by targeting the NF-𝜅B
and MAPK signaling pathways following pro-inflammatory
activation, as depicted in the model (Figure 2).
7.4. 𝛽-Arrestin-Biased Agonism. 𝛽-arrestin-biased agonism
has been shown for a variety of 𝛽2AR agonists [37]. These
agonists show preferential activation of noncanonical signal-
ing that favors 𝛽-arrestin-mediated signals from the receptor
over cAMP/PKA-mediated pathways. However, in the study
by Drake and colleagues, salmeterol was not amongst these
𝛽-arrestin-biased agonists. Significantly, these studies used
salmeterol at receptor-saturating 𝜇M concentrations and
showed that at these doses, salmeterol stimulated the produc-
tion of cAMP and instigated cAMP-induced signaling [37].
Qian et al., in a 2009 study, foundmuch the same results, that
at high concentration, salmeterol increased the production of
cAMP and downstream factors suchNADPHoxidase activity
[47]. These results are in sharp contrast to the effects of
low concentrations of the same agonist, namely, that 10−9 to
10−10M salmeterol does not stimulate increased cAMP and
its downstream effectors but activates a 𝛽-arrestin-mediated
reduction in some of these same downstream signaling events
[35]. A distinction between the 𝛽-arrestin biased agonists
and the nonbiased agonists reported by Drake et al. is the
existence of a different structural characteristic between the
two groups (the 𝛽-arrestin biased group all have an a-carbon
ethyl substituentmoiety lacking in the nonbiased group) [37].
It is interesting that Qian and colleagues essentially instigated
the same 𝛽-arrestin-favored signaling by drastically reducing
doses of salmeterol, a supposedly nonbiased 𝛽2AR agonist.
Thus, 𝛽2AR agonists provide wide possibilities for utilizing
biased signaling properties, fromwhatever mechanism of the
bias, to develop therapeutic potential in novel disease back-
grounds. In the case of inflammatory diseases such as Parkin-
son’s disease, agonists, such as salmeterol, might be used
therapeutically not only for their ability to inhibit inflam-
mation and stop progressive neurotoxicity, but also to stimu-
late preferential signaling cascades that foster neurogenesis.
Salmeterol applied at concentrations from 1 nM to 100 nM
has been shown to promote proliferation in adult rat dentate
gyrus-derived neural precursor cells (ADP) [50]. Further-
more, it has also been found that neural progenitor cell
proliferation is not necessarily cAMP-CREB-dependent [51].
Given that low doses of salmeterol preferentially stimulate
𝛽-arrestin signaling effectors as opposed to cAMP signaling
events, the potential for neurogenic effects is intriguing at the
least.
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8. Concluding Remarks
The neuroprotective effects of 𝛽2AR activation by higher
doses of 𝛽2AR agonists have been reported in other con-
ditions, such as amyotrophic lateral sclerosis [52], cerebral
ischemia [53], and spinal cord injury-induced locomotor dys-
function [54]. Although it is not yet clear how the 𝛽2AR
agonists exhibit all of these neuroprotective properties, sev-
eral studies have suggested that 𝛽2AR agonists function to
stimulate glutathione-dependent antioxidant processes from
nerve cells [30]. Meanwhile, others have reported that neu-
rotrophic factors from activated astrocytes induced by 𝛽2AR
agonists contribute to neuroprotection [55]. We propose that
the major neuroprotective activity of 𝛽2AR agonists in
Parkinson’s disease models is due to their anti-inflammatory
properties. It is clear that the effectiveness of the 𝛽2AR
agonist, salmeterol, and the other long-acting 𝛽2AR agonists
at low concentrations is due to their anti-inflammatory effect
on microglia and not to a direct protective effect on DA-
neurons or through an astrocyte-dependent effect. Given the
effectiveness of these compounds at such low concentrations
in inhibiting inflammatory responses, they appear to have
significant potential in regulating CNS inflammation and the






ROS: Reactive oxygen species
SN: Substantia nigra
TNF𝛼: Tumor necrosis factor 𝛼.
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